Nerve Growth Factor Applications in Alzheimer Disease Therapeutics

Nerve growth factor (NGF) has emerged as a pivotal neurotrophic agent in efforts to preserve and restore basal forebrain cholinergic neurons, which undergo early degeneration in Alzheimer disease. By supporting neuronal survival, synaptic maintenance and neurotransmitter synthesis, NGF-based interventions aim to counteract cognitive decline and neurodegeneration. Delivery strategies have evolved from direct protein infusion and gene therapy via viral vectors to advanced encapsulated cell biodelivery systems that release NGF locally within the cholinergic basal forebrain. In preclinical Alzheimer models, NGF enhancement has attenuated cholinergic marker loss, reduced amyloid burden and preserved memory performance. Clinical feasibility studies have demonstrated the safety and tolerability of NGF implants, with signs of stabilised cholinergic function and preserved cognitive scores. Remaining challenges include achieving sustained, controlled NGF release, minimising immune reactions and optimising device longevity. Recent innovations address microglial interactions with NGF-secreting cells and refine encapsulation scaffolds for consistent neurotrophin output. Together, these advances underscore NGF’s potential to modify disease trajectory by bolstering cholinergic circuitry, offering a complementary approach to amyloid- and tau-targeting therapies and highlighting its global significance as a regenerative strategy in Alzheimer disease management.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Nerve Growth Factor Applications in Alzheimer Disease Therapeutics publication trend

The graph below shows the total number of articles in nerve growth factor applications in alzheimer disease therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Nerve Growth Factor (NGF): A neurotrophin that supports survival and function of cholinergic neurons in the basal forebrain, critical for cognition.

Basal Forebrain Cholinergic Neurons: Neurones in the septal nucleus and nucleus basalis that produce acetylcholine and are among the earliest affected in Alzheimer disease.

Encapsulated Cell Biodelivery (ECB): A device-based approach in which genetically modified cells are enclosed within a semipermeable scaffold to secrete therapeutic factors directly into target brain regions.

Alpha-Frequency EEG Activity: Brain oscillations in the 8–12 Hz range, associated with wakeful rest and cognitive processing, used here as a functional biomarker of cholinergic integrity.

References

1. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimer's Research & Therapy (2016).
2. Fast Alpha Activity in EEG of Patients With Alzheimer’s Disease Is Paralleled by Changes in Cognition and Cholinergic Markers During Encapsulated Cell Biodelivery of Nerve Growth Factor. Frontiers in Aging Neuroscience (2022).
3. Microglia Impairs Proliferation and Induces Senescence In-Vitro in NGF Releasing Cells Used in Encapsulated Cell Biodelivery for Alzheimer’s Disease Therapy. International Journal of Molecular Sciences (2022).